Biotek-snakken — Maj 2018
-
-
Under the terms of the second agreement, Daiichi Sankyo will acquire licenses to Zymeworks’ Azymetric
and EFECT technology platforms to develop two additional bispecific antibody therapeutics. In exchange, Zymeworks will receive an upfront technology access fee of US$18 million and may receive up to US$466.7 million in potential clinical, regulatory and commercial milestone payments. In addition, Zymeworks will receive up to double-digit tiered royalties on global product sales. -
Jeg tror virkelig at man skal holde øje med BergenBio her op til ASCO. Hvis man vil ind , er dette nok den rette tid. Har heldigvis en lille portion allerede købt i 36.80. Men gode resultater på ASCO kan sikkert rykke kursen en del. Måske også det kunne dryppe på Genmab`s AXL.
-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind